Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

NCT03142152 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).

Interventions

  • DEVICE Carillon Mitral Contour System
  • OTHER Guideline Directed Heart Failure Medication

Study Locations (20)

California

  • Memorial Care Hospital — Long Beach
  • Keck School of Medicine of USC — Los Angeles
  • UCLA Medical Center — Los Angeles
  • Stanford University — Redwood City
  • Scripps Health — San Diego
  • University of California- San Francisco — San Francisco

Florida

  • Delray Medical Center — Delray Beach
  • University of Miami — Miami
  • Advent Health Hospital — Orlando
  • Palm Beach Gardens Medical — Palm Beach
  • Tallahassee Research Institute — Tallahassee
  • Tampa General Hospital — Tampa

Arizona

  • Dignity Health Research Institute at Mercy Gilbert and Chandler Regional Medical Centers — Gilbert
  • Banner Health - Phoenix — Phoenix
  • Tucson Medical Center Health — Tucson
  • Banner University Tuscon — Tucson

Georgia

  • Augusta University Research Institute — Augusta
  • Wellstar Health System, — Marietta

Colorado

  • South Denver Cardiology — Littleton

District of Columbia

  • Medstar — Washington D.C.

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2018-01-01
Est. Completion 2030-12-31
Phase NA

Sponsor

Cardiac Dimensions

28 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03142152

The ClinicalTrials.gov registry entry for NCT03142152 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiac Dimensions, which has 28 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions — of which Carillon Mitral Contour System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03142152 reports 20 study locations spanning 6 distinct geographic areas — top geographies include California, Florida, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03142152 about?

NCT03142152 is a clinical study titled "The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR". The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).

What is the current status of trial NCT03142152?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2018-01-01. Estimated completion is 2030-12-31.

What conditions does trial NCT03142152 study?

This clinical trial studies the following conditions: Heart Failure, Cardiovascular Diseases, Heart Diseases, Heart Valve Diseases, Mitral Valve Insufficiency. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03142152?

The interventions under investigation include: Carillon Mitral Contour System (DEVICE), Guideline Directed Heart Failure Medication (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03142152?

This trial is sponsored by Cardiac Dimensions, which has 28 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03142152 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial